TABLE 2.

Outcome summary by treatment group

Variable	Atomoxetine		Placebo		Test	p-value
Marijuana Dependence
Primary Outcome	Mean	SE	Mean	SE
Estimated (LSMean) Week 12 Self-Reported Use{b}	2.17	0.34	1.84	0.34	F Test (1, 35)	0.44
Secondary Efficacy Outcomes
Self-reported	Mean	SD	Mean	SD
% Days reporting use{a}	60.1%	31.5%	68.1%	31.3%	W ilcoxon Rank Sum	0.46
	N	%	N	%
Reduced days using relative to baseline	16	84.2%	13	68.4%	Fisher's Exact	0.45
Reduced amount using per using day relative to baseline	14	73.7%	16	84.2%	Fisher's Exact	0.69
Urine Drug Screens
	N	%	N	%
% of Samples Positive, as observed{c}	125	85.6%	105	83.3%	N/A	N/A
GEE Model-based estimate, % (SE)	87.3%	6.5%	85.3%	6.3%	GEE Wald Test	0.83
Clinician Global Impression	Mean	SD	Mean	SD
Improvement Rating, LOCF	2.84	1.12	2.95	1.08	W ilcoxon Rank Sum	0.65
Change in severity rating (last obs. - baseline)	−1.28	1.23	−1.33	1.46	W ilcoxon Rank Sum	1.00
	Mean	SD	Mean	SD
Marijuana Craving Questionnaire, change from baseline	−13.39	13.28	−17.05	15.97	W ilcoxon Rank Sum	0.56
ADHD	Mean	SD	Mean	SD
WRAADS, change from baseline & longitudinal	−15.05	10.96	−11.05	7.59	W ilcoxon Rank Sum	0.23
CAARS-SELF, change from baseline & longitudinal	−12.65	7.60	−10.16	7.73	W ilcoxon Rank Sum	0.34
CGI Improvement, LOCF	2.63	0.68	3.26	0.93	W ilcoxon Rank Sum	0.02
CGI Change in severity rating (last obs. - baseline)	−1.22	0.94	−0.89	1.28	W ilcoxon Rank Sum	0.21

^{a}For measures modeled longitudinally, the beta coefficient for the treatment by time interaction is reported.

^{b}Estimated mean is for the amount using per using day over the last seven days of self-reported use (last observation carried forward) from an ANCOVA model that adjusted for amount using per using day during the 90 days prior to the study.

^{c}A total of 272 UDS were collected, n=146 for the atomoxetine group, n=126